C

Cencora

Distributes medicines and supports patient care

Pharmacist - Pharmacy Support & Operations

Full-TimeUpdated on 10/20/2026
No salary listed
Mid
Bachelor's
Melbourne VIC, Australia
In Person
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • A degree in Pharmacy, or a diploma as a pharmacist in accordance with local regulations, is required.
  • Full command of English is required.
  • At least 2 years of experience in pharmacy support, medication fulfillment, healthcare operations, or a related field is required.
  • The role requires the ability to independently lift loads up to 20 kilograms using safe lifting methods covered in manual handling training.
  • Intermediate computer skills are required.
  • An understanding of import and export processes and statutory requirements is required.
  • Intermediate experience using Microsoft Office Suite, including Word, Excel, and Outlook, is required.
  • Sound numeracy and demonstrated attention to detail are required.
  • The role requires written and verbal communication skills in English.
  • The role requires the ability to work flexibly within tight schedules and variable workload demands.
  • The role requires participation in a 24/7 on-call roster, including telephone assistance and in-person emergency attendance for concerns involving product temperature control at the facility.
  • The role requires occasional scheduled weekend work for stock control and balance sheet processes.
  • The role requires work in temperature-controlled environments from +15 to +25°C, +2 to +8°C, and -20 to -30°C.
  • The role requires training in the Clinical Enterprise Resource Planning system and willingness to be trained to use Export Waiver Process equipment.
  • The role requires compliance with applicable regulatory and legal requirements, including Australian customs, aviation safety, quarantine and inspection, air transport, and quality-management requirements.
Responsibilities
  • Verify and sign operational jobs, and release shipments for distribution.
  • Manage product-status changes physically and in systems according to client instructions and applicable internal guidelines.
  • Ensure compliance with government, legislative, local health, regulatory, and legal requirements and applicable company procedures and standards.
  • Follow World Courier Standard Operating Procedures for daily depot activities from product receipt through storage, shipment or delivery to sites, and returns when required.
  • Lead secondary-packaging relabeling tasks using packaging instruction forms and ensure compliance with Good Manufacturing Practices and Global Distribution Practice.
  • Perform quality checks on relabeling processes when the Local Quality Representative is absent or the Quality Department assigns this function.
  • Maintain detailed knowledge of depot protocols and provide instructions to depot staff.
  • Verify and organize received documentation, shipment-arrival conditions, storage information, and other documentation related to products received at the depot.
  • Contact World Courier customers daily to support them with protocols stored at the depot.
  • Maintain knowledge of depot facilities and equipment.
  • Assist the Team Leader with work allocation, daily schedules, and personnel management; identify potential personnel-management issues affecting work schedules.
  • Ensure expired stock is moved to Quarantine status.
  • Participate in authoring and reviewing global and local Standard Operating Procedures, work instructions, and Tracking Reference Number documents.
  • Physically pack inbound, outbound, and returned shipments using Cencora World Courier packaging products.
  • Lead continuous-improvement initiatives to streamline processes.
  • Collaborate with applicable company departments to prepare accurate, timely reports.
  • Keep internal stakeholders informed about order and shipment progress; collaborate with them to resolve clinical and commercial matters and support client satisfaction.
  • Liaise with the Transport Customer Service team regarding World Courier transport bookings and ensure the correct processes are followed.
  • Provide information to World Courier Australia business units to coordinate work output effectively.
  • Share ideas, experiences, and recommendations in team and organization-wide discussions to improve business effectiveness and efficiency.
  • Collaborate with internal stakeholders to ensure the function operates effectively and efficiently while maintaining a harmonious team environment.
  • Follow policies and procedures to support consistent national practices aligned with strategic objectives.
  • Promote a safe and healthy workplace, take reasonable care for personal and others' health and safety, report accidents, incidents, and hazards promptly, and identify and address issues under applicable workplace health and safety legislation and company policy.
  • Perform other duties for which the employee has been trained.
Desired Qualifications
  • Certification in pharmacy technician registration, a recognized pharmacy technician credential under local regulations, or an equivalent credential is preferred.
  • Experience in a management role is preferred.
  • Experience in the clinical trial business is preferred.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.